Amrutanjan Health Care Q1 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹1,435 Cr
- P/E
- 23.07
- ROE
- 18.42%
- PEG
- 1.32
- Price to sales
- 2.81
- Debt to equity
- 0.00
- 52W high / low
- ₹730 / ₹488
- Sales growth (5Y)
- 8.59%
- EBITDA margin
- 14.37%
- Net profit margin
- 12.77%
- Promoter holding
- 46.52%
- Sales (last year)
- ₹511 Cr
Guidance scorecard · Q1 FY27 call
What Amrutanjan Health Care Ltd's management guided
and where it ranks in Pharmaceuticals & Biotechnology
RevenueQ1 FY25 call
10–20%- The company is cautiously optimistic about growth returning to the core pain category, which showed degrowth post-COVID but is now growing at low double-digit rates.
- Sales growth in brands Amrutanjan, Comfy, and ElectroPlus is expected to drive margin expansion and overall revenue growth.
- The target is to achieve Rs 1000 crore turnover by 2028, viewed as an aspirational but achievable milestone.
- Distribution expansion is a key focus, especially adding 1 lakh new chemical shops in rural Maharashtra over 2-3 years to drive growth.
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
MarginsQ1 FY25 call
Up 2%+See what Amrutanjan Health Care Ltd said on margins — free account, 30 seconds.
CapexQ1 FY25 call
Planned- The board approved a CapEx of Rs 123 crores for a new Comfy plant (announced in May).
- Business utilization rates are currently around 60%, so no major additional CapEx is foreseen beyond this.
- The Rs 123 crores CapEx for the Comfy plant is the large upcoming investment.
- The company aims to improve margins by expanding the growth of key brands—including Amrutanjan, Comfy, and ElectroPlus—expecting margin expansion by about 200 basis points.
2 more points from Amrutanjan Health Care Ltd's call on capex
Create a free account to keep reading this call
FundraisingQ1 FY25 call
See what Amrutanjan Health Care Ltd said on fundraising — free account, 30 seconds.
Order bookQ1 FY25 call
- Focus areas discussed: revenue growth targets, product distribution, market expansion.
- Emphasis on brand growth (Amrutanjan, Comfy, ElectroPlus) and increasing market share.
- Customer experience, innovation, and competition addressed without order backlog details.
Ranges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹556 Cr | 22.1 | |
| 2 | 40%+ | Up 0–2% | ₹215 Cr | 22.2 | |
| 3 | 40%+ | Flat | ₹16,144 Cr | — | |
| 4 | 40%+ | Flat | ₹6,072 Cr | 48.0 | |
| 5 | 40%+ | Flat | ₹40 Cr | — | |
| 6 | 20–40% | Up 2%+ | ₹50,220 Cr | 43.8 |
Sign up free to see every company in the sector ranking and track Amrutanjan Health Care Ltd.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingFinancials of Amrutanjan Health Care Ltd
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Amrutanjan Health Care Ltd
Quarterly Results
Quarter-by-quarter operating performance
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 100 | 78 | 99 | 117 | 127 | 84 | 110 | 123 | 135 | 94 | 118 | 141 | 150 |
| Expenses + | 87 | 71 | 92 | 95 | 111 | 80 | 96 | 99 | 118 | 86 | 101 | 116 | 124 |
| Operating Profit | 13 | 7 | 7 | 22 | 16 | 4 | 14 | 23 | 18 | 8 | 17 | 25 | 26 |
| OPM % | 13% | 9% | 7% | 18% | 13% | 4% | 12% | 19% | 13% | 9% | 14% | 18% | 17% |
| Other Income + | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 4 | 5 | 4 | 4 | 3 | -3 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 16 | 9 | 9 | 24 | 20 | 6 | 16 | 26 | 21 | 11 | 19 | 26 | 21 |
| Tax % | 23% | 26% | 26% | 26% | 30% | 27% | 26% | 26% | 27% | 26% | 27% | 26% | 23% |
| Net Profit + | 13 | 7 | 7 | 17 | 14 | 5 | 12 | 19 | 15 | 8 | 14 | 19 | 16 |
| EPS in Rs | 4.34 | 2.40 | 2.37 | 6.04 | 4.72 | 1.60 | 4.08 | 6.66 | 5.25 | 2.87 | 4.83 | 6.73 | 5.60 |
Financials of Amrutanjan Health Care Ltd
Profit & Loss
Annual income statement trend
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales + | 154 | 174 | 207 | 220 | 253 | 261 | 333 | 406 | 380 | 421 | 452 | 503 |
| Expenses + | 130 | 143 | 178 | 192 | 222 | 231 | 258 | 326 | 335 | 369 | 394 | 427 |
| Operating Profit | 25 | 32 | 29 | 28 | 31 | 31 | 75 | 80 | 45 | 52 | 58 | 76 |
| OPM % | 16% | 18% | 14% | 13% | 12% | 12% | 22% | 20% | 12% | 12% | 13% | 15% |
| Other Income + | 5 | 6 | 7 | 8 | 7 | 8 | 11 | 15 | 15 | 16 | 18 | 9 |
| Interest | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 |
| Depreciation | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 | 5 | 6 | 7 | 6 |
| Profit before tax | 26 | 35 | 34 | 33 | 35 | 34 | 82 | 91 | 54 | 62 | 69 | 78 |
| Tax % | 35% | 35% | 35% | 39% | 29% | 27% | 25% | 26% | 26% | 27% | 26% | 26% |
| Net Profit + | 17 | 22 | 22 | 20 | 25 | 25 | 61 | 67 | 40 | 45 | 51 | 58 |
| EPS in Rs | 5.86 | 7.68 | 7.47 | 6.84 | 8.39 | 8.58 | 20.93 | 22.99 | 13.63 | 15.55 | 17.58 | 20.03 |
| Dividend Payout % | 30% | 25% | 26% | 22% | 26% | 24% | 20% | 20% | 34% | 30% | 26% | 0% |
Financials of Amrutanjan Health Care Ltd
Balance Sheet
Capital structure and asset base
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 102 | 118 | 113 | 126 | 143 | 156 | 213 | 262 | 288 | 286 | 324 | 367 |
| Borrowings + | 0 | 0 | 2 | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 2 | 2 |
| Other Liabilities + | 25 | 28 | 34 | 38 | 42 | 44 | 57 | 84 | 70 | 77 | 93 | 137 |
| Total Liabilities | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 509 |
| Fixed Assets + | 13 | 22 | 27 | 28 | 26 | 26 | 23 | 28 | 49 | 50 | 49 | 51 |
| CWIP | 4 | 1 | 1 | 0 | 0 | 0 | 2 | 17 | 1 | 2 | 16 | 105 |
| Investments | 14 | 10 | 10 | 8 | 18 | 18 | 18 | 13 | 5 | 0 | 0 | 3 |
| Other Assets + | 100 | 116 | 115 | 131 | 144 | 161 | 232 | 291 | 307 | 315 | 356 | 349 |
| Total Assets | 130 | 149 | 152 | 166 | 188 | 205 | 274 | 350 | 362 | 367 | 421 | 509 |
Financials of Amrutanjan Health Care Ltd
Cash Flows
Operating, investing and financing cash movement
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operating Activity + | 19 | 21 | 8 | 19 | 21 | 18 | 91 | 52 | 20 | 28 | 51 | 36 |
| Cash from Investing Activity + | -5 | 1 | -0 | -8 | -11 | -14 | -88 | -36 | -2 | 19 | -31 | -21 |
| Cash from Financing Activity + | -12 | -11 | -5 | -9 | -7 | -12 | -7 | -17 | -15 | -48 | -13 | -14 |
| Net Cash Flow | 2 | 12 | 3 | 2 | 3 | -7 | -4 | -1 | 3 | -1 | 6 | 1 |
| Free Cash Flow | 13 | 20 | 5 | 18 | 19 | 16 | 89 | 29 | 11 | 21 | 15 | -19 |
| CFO/OP | 114% | 104% | 77% | 105% | 101% | 95% | 146% | 96% | 81% | 86% | 118% | 73% |
Financials of Amrutanjan Health Care Ltd
Ratios
Working capital efficiency and return ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 62 | 55 | 51 | 46 | 47 | 37 | 19 | 34 | 32 | 42 | 45 | 44 |
| Inventory Days | 44 | 44 | 44 | 40 | 45 | 74 | 45 | 53 | 58 | 50 | 45 | 56 |
| Days Payable | 46 | 51 | 110 | 102 | 92 | 98 | 106 | 122 | 95 | 96 | 113 | 106 |
| Cash Conversion Cycle | 61 | 48 | -15 | -16 | 0 | 13 | -41 | -35 | -6 | -5 | -23 | -6 |
| Working Capital Days | 42 | 45 | 76 | 26 | 30 | 70 | 28 | 92 | 117 | 173 | 99 | 96 |
| ROCE % | 26% | 29% | 28% | 25% | 25% | 23% | 44% | 38% | 19% | 21% | 22% | 25% |
Momentum score · price trend
17 out of 100 — Cooling
Over the past year its share price has done worse than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | −32.0% | 21% |
| Last 6 months | −13.1% | 33% |
| Last 3 months | −3.6% | 60% |
The price is 49.3% below its all-time high of ₹979.25 (4 Nov 2021). Stocks more than 20% below their peak have their score halved, so 34 became 17.
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Amrutanjan Health Care Ltd: 0.4 × 21 + 0.4 × 33 + 0.2 × 60 = 34, halved to 17 because the price is more than 20% below its all-time high.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 30 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Amrutanjan Health Care Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Accretion Pharmaceuticals Ltd (Q2 FY27)
25.85% increase) . Key results statement takeaways from Accretion Pharmaceuticals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.
- Sigachi Industries Ltd (Q2 FY27)
Year-on-Year (YoY) Revenue Growth: 18.09% (Q2 FY27 vs Q2 FY26) . Key investor presentation takeaways from Sigachi Industries Ltd's Q2 FY27 investor presentation
- Advanced Enzyme Technologies Ltd (Q2 FY27)
Q2 FY27 revenue from operations: ₹2,145 million, up 16% YoY from ₹1,845 million in Q2 FY26 (Page 13, 5). Key investor presentation takeaways from Advanced Enzym
- IOL Chemicals (Q2 FY27)
Q2 FY27 revenue from operations: ₹795.0 Cr, a 40.1% year-on-year (YoY) increase from ₹567.5 Cr in Q2 FY26 (Page 7). Key investor presentation takeaways from IOL